Preclinical antitumor activity of CI-973,[SP-4-3-(R)]-[1,1-cyclobutanedicarboxylato(2-)] (2 methyl-1,4-butane-diamine-N,N′)platinum

Abstract

The antitumor activity of [SP-4-3-(R)]-[1,1-cyclobutanedicarboxylato-(2-)](2 methyl-1,4-butanediamine-N,N′)platinum (CI-973) was characterized in a number of preclinical model systems. CI-973 retained substantial activity in cisplatin resistant murine leukemia cell lines, in vitro and in vivo; in L1210 leukemia resistant to cisplatin in vivo, CI-973 retained as much activity as was found in animals bearing sensitive L1210 leukemia. When compared in five solid murine tumors in vivo, both CI-973 and cisplatin were approximately equivalent in activity. In one human colon tumor and one human non-small cell lung carcinoma tested as xenografts in immunodeficient mice, cisplatin and CI-973 were ineffective. In two other human non-small cell lung carcinomas tested in the same fashion, cisplatin did possess activity. CI-973 has entered phase I clinical trials.

DOI: 10.1007/BF00194538

8 Figures and Tables

Statistics

010002000'94'97'00'03'06'09'12'15
Citations per Year

245 Citations

Semantic Scholar estimates that this publication has 245 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Kraker1991PreclinicalAA, title={Preclinical antitumor activity of CI-973,[SP-4-3-(R)]-[1,1-cyclobutanedicarboxylato(2-)] (2 methyl-1,4-butane-diamine-N,N′)platinum}, author={Alan J. Kraker and Charles W. Moore and Billy J. Roberts and Wilbur R. Leopold and William Leland Elliott}, journal={Investigational New Drugs}, year={1991}, volume={9}, pages={1-8} }